Combination therapy for ovarian cancer that is resistant to platinum
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (utidelone and fruquintinib) for ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have ovarian, fallopian tube, or primary peritoneal cancer that is a common type (not clear cell, mucinous, or sarcoma).
- Your cancer has come back or grown within 6 months after finishing platinum-based chemotherapy.
- You have at least one tumor that can be measured on a scan.
- You have not had more than 3 previous lines of cancer treatment (not counting chemotherapy given before or after surgery unless your cancer progressed quickly).
- You are physically active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this new combination can shrink tumors or slow the disease.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This trial tests a new oral medication, utidelone, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemotherapy. The goal is to see if utidelone can help control the cancer and potentially slow its growth.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
Hear when a new Platinum-resistant Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.